# Study of Pemetrexed Plus Cisplatin in Advanced Gastric Cancer

> **NCT00320515** · PHASE1,PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 89 (actual)

## Conditions studied

- Neoplasm, Gastric

## Interventions

- **DRUG:** pemetrexed
- **DRUG:** cisplatin

## Key facts

- **NCT ID:** NCT00320515
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2009-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00320515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00320515, "Study of Pemetrexed Plus Cisplatin in Advanced Gastric Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00320515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*